Nanopath, a Cambridge, MA-based molecular diagnostics company, raised $10M in Series A funding.
The round was led by Norwest Venture Partners and the Medtech Convergence Fund, with participation from Gingerbread Capital and Green D Ventures. Jeff Crowe, senior managing partner at Norwest Venture Partners, and Aaron Sandoski, founding partner at SV Health Investors’ Medtech Convergence Fund, joined Nanopath’s board in tandem with this funding round.
The company intends to use the funds to support development and commercialization of its biosensing platform.
Led by CEO Amogha Tadimety, and CTO Alison Burklund, Ph.D., Nanopath is dedicated to improving health equity worldwide, starting with women’s health. Its proprietary molecular diagnostic test leverages novel biosensing technology, which aims to improve how women’s pelvic and gynecologic infections are diagnosed, and enable fast, high-complexity tests to be performed in minutes and at the point-of-care.
Nanopath’s proprietary biosensing technology utilizes ultrasensitive optical detection to identify DNAs and RNAs, without the need for nucleic acid amplification. This amplification-free approach minimizes reagents, lowers costs and reduces user steps that are ubiquitous across molecular diagnostics.
The company is headquartered in Cambridge, Mass., at LabCentral, the premier launchpad for high-potential life sciences and biotech start-ups. Nanopath was spun out of Dartmouth College in 2019 in partnership with Dartmouth Hitchcock Medical Center.
FinSMEs
10/08/2022